Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS–Sponsored by AbbVie Medical Affairs

Sep 30, 2022 1:51 pm
Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Subscribe and Rate

Subscribe to the RheumNow podcast on your favorite podcast app to get automatic downloads of the latest content. Listen in the car, airplane, anywhere! We also reach more listeners through reviews from our users. Consider leaving a review!
 

 

×